Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has provided an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the approval of its core product, trastuzumab botidotin, by the National Medical Products Administration for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received prior anti-HER2 therapy. This approval, based on a Phase 3 study demonstrating significant improvement in progression-free survival, positions the company as a competitive player in the oncology market, potentially impacting its market presence and offering new treatment options for patients.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$548.60 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates (ADCs), with a particular emphasis on targeting human epidermal growth factor receptor 2 (HER2) positive cancers.
Average Trading Volume: 819,970
Technical Sentiment Signal: Buy
Current Market Cap: HK$110.4B
For an in-depth examination of 6990 stock, go to TipRanks’ Overview page.